2013
Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer
Abu-Khalaf M, Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. The Breast 2013, 22: s83-s87. PMID: 24074799, DOI: 10.1016/j.breast.2013.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntineoplastic Agents, HormonalBiopsy, NeedleBreast NeoplasmsChemotherapy, AdjuvantCost SavingsCost-Benefit AnalysisFemaleForecastingGenetic TestingGenomicsHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisReceptors, EstrogenRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsLow-risk patientsBreast cancerRisk patientsTreatment recommendationsEarly-stage breast cancerER-positive breast cancerUse of chemotherapyInvasive breast cancerGenomic testingStage breast cancerInternational practice guidelinesMultivariate prognostic modelCost-effectiveness studiesPotential clinical valueAdjuvant treatmentBreast cancer biomarkersCurrent guidelinesPractice guidelinesClinical utilityClinical valueTumor markersStage IPrognostic modelPrognostic testClinical use
2011
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals Of Surgical Oncology 2011, 19: 1508-1516. PMID: 22193884, DOI: 10.1245/s10434-011-2108-2.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPrimary breast cancerBreast cancerSystemic therapyBreast-conserving surgery rateLarge adjuvant trialsPathologic complete responseInflammatory breast cancerNew therapeutic regimensIntermediate end pointsInternational Consensus ConferenceClinical research groupAdjuvant trialsNew regimensPathologic responseComplete responseSurgery ratesTherapeutic regimensConsensus conferenceEnd pointTherapyCancerTrialsRegimensPanel of representativesA Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA 2011, 305: 1873-1881. PMID: 21558518, PMCID: PMC5638042, DOI: 10.1001/jama.2011.593.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlgorithmsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreast NeoplasmsBridged-Ring CompoundsDisease-Free SurvivalDrug Resistance, NeoplasmFemaleForecastingGene Expression ProfilingGenes, erbB-2Genes, NeoplasmGenomicsHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProspective StudiesReceptors, EstrogenRiskTaxoidsConceptsDistant relapse-free survivalInvasive breast cancerBreast cancerGenomic predictorsD. Anderson Cancer CenterAnthracycline-based regimensER-negative subsetExcellent pathologic responseProspective multicenter studyRelapse-free survivalAbsolute risk reductionStandard cancer treatmentPredictors of responseIndependent validation cohortAnderson Cancer CenterNegative breast cancerCancer treatment strategiesSequential taxaneNeoadjuvant chemotherapyPreoperative chemotherapyPathologic responseWorse survivalEndocrine sensitivityER statusMulticenter study